Aptinib shows increased overall survival in Patients with Thyroid Cancer: JAMA

Apatinib showed substantial therapeutic advantages in both extended Progression Free Survival (PFS) and overall survival with a tolerable safety profile in patients with progressive locally advanced or metastatic RAIR-DTC in a new research led by Yansong Lin and colleagues. At the predetermined intermediate analysis, the REALITY study fulfilled its primary end goal of PFS.

The findings of this study was published in the Journal of American Medical Association on 16th December, 2021.

Radioactive iodine–refractory differentiated thyroid cancer (RAIR-DTC) patients have a dismal prognosis and few therapy choices. As a result, the goal of this research was to evaluate the effectiveness and safety of apatinib, a highly selective vascular endothelial growth factor (VEGFR-2) inhibitor, in patients with locally progressed or metastatic RAIR-DTC.

This randomized, double-blind, placebo-controlled phase 3 trial was conducted in 92 patients with progressive locally advanced or metastatic RAIR-DTC at 21 sites in China between February 17, 2017 and March 2, 2020, with the data cutoff date for this analysis being March 25, 2020. Patients were randomized at random (1:1) to receive apatinib, 500 mg/d, or a placebo. Patients who experienced progression while on placebo were permitted to switch to apatinib. for this research The primary endpoint was PFS as determined by the investigator. Overall survival, objective response rate (ORR), disease control rate (DCR), length of response, time to objective response, and safety were secondary end goals. To assess effectiveness, intention-to-treat analyses were used.